質子幫浦抑制劑市場：按類型、適應症、劑型、通路、地區

質子幫浦抑制劑的全球市場規模預計到2024年為38.1億美元，預計到2031年將達到55億美元，2024年至2031年的複合年成長率為5.4%。

圖 1. 2024 年質子幫浦抑制劑市場佔有率(%)，依地區分類

質子幫浦抑制劑 (PPI) 是一組透過減少胃酸產生量來發揮作用的藥物。 PPI 通常用於治療胃酸倒流、潰瘍和食道發炎。 PPI 透過抑制胃壁細胞表面質子幫浦酶的作用發揮作用。這種酵素負責運輸有助於在胃中產生鹽酸的離子。透過抑制這種泵，質子幫浦抑制劑可以減少胃酸的產生並緩解胃酸過多的症狀。酸相關疾病盛行率的增加、患有此類疾病的老年人口的增加以及醫療保健支出的增加可能會在不久的將來推動全球質子幫浦抑制劑市場的成長。

市場動態：

消化性潰瘍和胃食道逆流（GERD）等酸相關疾病的全球盛行率不斷上升，可能會推動全球質子幫浦抑制劑市場的成長。由於飲食和生活方式的改變，胃食道逆流症在世界各地變得非常普遍。據估計，GERD 影響著北美 20% 以上的人口。質子幫浦抑制劑是 GERD 患者的第一線藥物。老年人口的增加也將推動市場成長，因為老年人更容易罹患與酸相關的疾病。然而，長期使用 PPI 相關的副作用，如腎損傷、骨折、肺炎和營養吸收受損，可能會阻礙市場成長。新興國家消化器官系統健康意識的提高和醫療保健成本的上升可能為市場參與企業提供機會。

本研究的主要特點

• 該報告對全球質子幫浦抑制劑市場進行了詳細分析，以2023年為基準年估計了預測期內（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
• 它還揭示了各個細分市場的潛在商機，並解釋了該市場中有吸引力的投資提案的矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
• 它根據公司亮點、產品系列、主要亮點、財務業績和策略等參數，介紹了全球質子幫浦抑制劑市場的主要企業。
• 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球質子幫浦抑制劑市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
• 透過用於全球質子幫浦抑制劑市場分析的各種策略矩陣，將促進相關人員的決策。

目錄

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行概述
• 一致的機會地圖 (COM)

第3章 市場動態、法規與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因素
  • 機會
• 影響分析
• 市場趨勢
• 監管場景
• 收購和合作場景
• 資金籌措和投資
• PEST分析
• 波特的分析

第4章全球質子幫浦抑制劑市場－冠狀病毒（COVID-19）大流行的影響

• 整體影響
• 政府舉措
• COVID-19 對市場的影響

第5章全球質子幫浦抑制劑市場，按類型，2019-2031（十億美元）

• 介紹
• 奧美拉唑
• 泮他拉唑
• Rabeprazole
• 地克蘭索拉唑
• 蘭索拉唑
• 其他

第6章 2019-2031 年全球質子幫浦抑制劑市場（依指標分類）（十億美元）

• 介紹
• 潰瘍
• 胃食道逆流症
• 其他

第7章全球質子幫浦抑制劑市場，依通路，2019-2031（十億美元）

• 介紹
• 錠劑
• 膠囊
• 注射
• 其他

第8章全球質子幫浦抑制劑市場，按劑型，2019-2031（十億美元）

• 介紹
• 醫院藥房
• 零售藥房
• 網路藥房

第9章全球質子幫浦抑制劑市場，按地區，2019-2031（十億美元）

• 介紹
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東

第10章競爭格局

• 公司簡介
  • AstraZeneca
  • Pfizer
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Procter &Gamble
  • Johnson &Johnson
  • GlaxoSmithKline plc
  • Bayer AG
  • Eisai Co., Ltd.
  • Merck &Co., Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Allergan, Inc.
  • Cadila Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Perrigo Company PLC.

第11章分析師建議

• 升起和降落
• 綜合機會圖

第12章參考文獻與調查方法

• 參考
• 調查方法

Global proton pump inhibitors market is estimated to be valued at USD 3.81 Bn in 2024 and is expected to reach USD 5.50 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

Figure 1. Proton Pump Inhibitors Market Share (%), By Region, 2024

Proton pump inhibitors (PPIs) are a group of medicines that work by reducing the amount of acid produced in the stomach. PPIs are commonly used to treat acid reflux, ulcers, and inflammation of the esophagus. These work by blocking the action of the proton pump, an enzyme on the surface of gastric parietal cells. This enzyme is responsible for transportation of ions that aid in the production of hydrochloric acid in the stomach. By inhibiting this pump, PPIs decrease acid production and offer relief from conditions caused by excess stomach acid. Growing prevalence of acid related diseases, increasing aging population suffering from such diseases, rising healthcare expenditure can drive the global proton pump inhibitors market growth in the near future.

Market Dynamics:

Rising prevalence of acid-related diseases such as peptic ulcer disease and gastroesophageal reflux disease (GERD) around the world can drive the global proton pump inhibitors market growth. GERD has become highly common worldwide due to changing dietary patterns and lifestyle changes. According to some estimates, GERD affects over 20% of the population in North America. Proton pump inhibitors are first line treatment for GERD patients. Growing geriatric population can also drive the market growth as older people are more prone to acid-related disorders. However, side effects associated with long-term PPI usage such as kidney problems, bone fractures, pneumonia, and interference with absorption of nutrients can hamper the market growth. Growing awareness regarding digestive health and rising healthcare expenditure in emerging nations can offer opportunities for the market players.

Key Features of the Study:

• This report provides in-depth analysis of the global proton pump inhibitors market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global proton pump inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca, Pfizer, Johnson and Johnson, and Bayer
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global proton pump inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global proton pump inhibitors market

Detailed Segmentation-

• By Type
  • Omeprazole
  • Pantaprazole
  • Rabeprazole
  • Dexlansoprazole
  • lansoprazole
  • Others
• By Disease Indication
  • Ulcers
  • Gastroesophageal Reflux Disease
  • Others
• By Dosage Form
  • Tablet
  • Capsules
  • Injection
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca
  • Pfizer
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Procter & Gamble
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Bayer AG
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Reddy's Laboratories Ltd.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Allergan, Inc.
  • Cadila Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Perrigo Company PLC

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Disease Indication
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Proton Pump Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Proton Pump Inhibitors Market, By Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Omeprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Pantaprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Rabeprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Dexlansoprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Lansoprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Proton Pump Inhibitors Market, By Disease Indication, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Ulcers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Gastroesophageal Reflux Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Proton Pump Inhibitors Market, By Dosage Form, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Tablet
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Capsules
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Injection
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Proton Pump Inhibitors Market, By Dosage Form, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Proton Pump Inhibitors Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • AstraZeneca
    • Company Highlights
    • Disease Indication Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Procter & Gamble
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Bayer AG
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Allergan, Inc.
  • Cadila Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Perrigo Company PLC.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. Reference and Research Methodology

• References
• Research Methodology
• About us and Sales Contact